Financial Performance - The unaudited revenue of RMH Holdings Limited for the three months ended March 31, 2022, was approximately S$3,311,000, representing an increase of approximately S$1,151,000 or 53.3% compared to S$2,160,000 for the same period in 2021[7][11]. - The unaudited loss for the Group was approximately S$2,529,000 for the three months ended March 31, 2022, which is an increase of approximately S$1,621,000 or 178.5% compared to a loss of S$908,000 for the same period in 2021[8][11]. - Loss per share for the Company was approximately 0.27 Singapore cents for the three months ended March 31, 2022, compared to approximately 0.13 Singapore cents for the same period in 2021[9][11]. - The total comprehensive loss for the period was S$2,529,000, reflecting the overall financial performance of the Group[13]. - The Group's other operating income for the three months ended March 31, 2022, was S$223,000, compared to S$295,000 for the same period in 2021[13]. - The total comprehensive loss includes a foreign currency translation income of S$22,000 for the period[13]. - The Group's total equity as of March 31, 2022, was S$9,253,000, reflecting the financial position of the Company[15]. - The increase in losses was attributed to higher operating expenses and costs associated with the Group's activities during the period[8][11]. Revenue Breakdown - Revenue for the three months ended March 31, 2022, was S$3,311,000, representing a 53% increase from S$2,160,000 in the same period of 2021[36]. - Aesthetic services revenue increased to S$149,000 from S$88,000, a growth of 69% year-over-year[36]. - Consultation services revenue rose to S$541,000, up 21% from S$448,000 in the previous year[36]. - Trading sales surged to S$760,000 compared to S$31,000 in the same period last year, indicating a significant increase[36]. - Revenue recognized at a point in time was S$1,990,000, up from S$1,033,000, reflecting a 92% increase[36]. - Revenue recognized over time was S$1,321,000, compared to S$1,127,000, marking a 17% increase[36]. - Revenue from Singapore was S$2,551,000, up from S$2,160,000 in 2021, while revenue from Hong Kong was S$760,000, which was not reported in the previous year[42]. - Revenue from Aesthetic Services rose by approximately S$61,000 from S$88,000 for the three months ended March 31, 2021 to S$149,000 for the three months ended March 31, 2022[73]. - Revenue from Consultation Services increased by approximately S$93,000 from S$448,000 for the three months ended March 31, 2021 to S$541,000 for the three months ended March 31, 2022, with patient visits rising by 22.1%[75]. - Revenue from Prescription and Dispensing Services increased by approximately S$211,000 from S$675,000 in Q1 2021 to S$886,000 in Q1 2022, reflecting an increase in patient visits[77]. - Revenue from Treatment Services rose by approximately S$39,000 from S$591,000 in Q1 2021 to S$630,000 in Q1 2022, driven by excision, skin check, kenacort, and cryosurgery[77]. - Revenue from Other Services increased by approximately S$18,000 from S$327,000 in Q1 2021 to S$345,000 in Q1 2022, primarily from laboratory tests and medical examinations[77]. - Trading Sales contributed approximately S$760,000 in Q1 2022, an increase of approximately S$729,000 compared to S$31,000 in Q1 2021[77]. Operating Expenses - The company reported a loss before tax, with significant expenses including professional and consulting fees amounting to S$1,122,000, compared to S$717,000 in 2021[53]. - Employee benefits expense rose to S$1,951,000 in Q1 2022 from S$1,175,000 in Q1 2021, largely due to additional dermatologists[83]. - Other operating expenses increased by approximately S$1,008,000 or 119% from S$847,000 in Q1 2021 to S$1,855,000 in Q1 2022[93]. - Other operating income decreased by S$72,000 from approximately S$295,000 in Q1 2021 to approximately S$223,000 in Q1 2022[80]. - Consumables and medical supplies used increased to approximately S$1,138,000 in Q1 2022 from S$330,000 in Q1 2021, in line with revenue growth[80]. - Other expenses increased due to nonrecurring marketing and advertising expenses aimed at creating market awareness for the new aesthetic clinic[99]. Corporate Governance - The company adopted the Corporate Governance Code and complied with all applicable provisions during the three months ended March 31, 2022[120]. - The board is committed to high standards of corporate governance to manage business risks and enhance transparency[119]. - The Audit Committee consists of three independent non-executive Directors, ensuring compliance with GEM Listing Rules[128]. - The Audit Committee reviewed the Group's unaudited condensed consolidated financial statements for the three months ended March 31, 2022[129]. - All directors confirmed compliance with the required standard of dealings regarding securities transactions during the reporting period[123]. - The board will continue to review and improve the company's corporate governance practices[119]. Shareholder Information - The company had a significant shareholder, Dr. Loh Teck Hiong, holding 210,024,000 shares, representing 16.21% of the company[104]. - As of March 31, 2022, Brisk Success holds 210,024,000 shares, representing a 16.21% interest in the company[115]. - HK MZ Health Investment holds 132,968,000 shares, accounting for 10.26% of the company's interest[115]. - No share options were granted by the company from September 22, 2017, to the date of the report[123]. - The company and its subsidiaries did not purchase, sell, or redeem any shares during the three months ended March 31, 2022[123]. - No rights to acquire shares or debentures were granted to directors or their family members during the reporting period[123]. - The company has not disclosed any interests or short positions in shares that require disclosure under the SFO as of March 31, 2022[118]. Future Outlook - The company continues to focus on strategic initiatives to enhance its market position and operational efficiency moving forward[11]. - The Group expects continued improvement in revenue at a faster rate from clinics in both Singapore and Hong Kong due to easing COVID-19 measures[65]. - The Company is cautiously optimistic about returning to profitability in the second quarter of 2022[65]. - The sales of Regenerative Medicine products remained lackluster due to the continued closure of the Hong Kong-China border[65].
德斯控股(08437) - 2022 Q1 - 季度财报